A Study of SHR-1316 and Fluzoparib（SHR-3162） in Small Cell Lung Cancer Patients
The purpose of this study is to evaluate the safety and efficacy of SHR-1316 in combination with Fluzoparib（SHR-3162） in Small Cell Lung Cancer Patients
Small Cell Lung Cancer
DRUG: 1.Experimental: A (Part 1): Fluzoparib and SHR -1316|DRUG: 2.Experimental: B (Part 1): Fluzoparib and SHR -1316|DRUG: 3.Experimental: C (Part 2): Fluzoparib and SHR -1316 Expansion
Part 1: 1.Number of Participants with AEs and SAEs, Up to approximately 24 months.|Part 1: 2. RP2D: Recommended dose for phase II study, Up to approximately 24 months.|Part 2: 1. ORR: Percentage of Participants With a CR or PR, Up to approximately 24 months.
Part 1: 1. ORR: Percentage of Participants With a CR or PR, Up to approximately 24 months.|Part 2: 1.Number of Participants with AEs and SAEs, Up to approximately 24 months.|Part 2: 2.DoR: Percentage of Participants With a CR or PR, Up to approximately 24 months.|Part 2: 3. DCR: Percentage of participants in the analysis population who have a CR, PR or SD per RECIST 1.1., Up to approximately 24 months.|Part 2: 4. PFS: PFS is defined as the time from randomization to the first documented disease progression per RECIST 1.1 based on blinded independent central review or death due to any cause, whichever occurs first., Up to approximately 24 months.|Part 2: 5. OS: Baseline until death from any cause, Up to approximately 24 months.
The purpose of this study is to evaluate the safety and efficacy of SHR-1316 in combination with Fluzoparib（SHR-3162） in Small Cell Lung Cancer Patients